The FDA has cleared Roctavian, BioMarin’s one-time therapy for adults with severe hemophilia A. Hemophilia A affects about 1 in 10,000 people. The medication was initially rejected in 2020 and had a review delay earlier this year but has finally received approval.
Click here to read the entire article.